ALSO NOTED: Deltagen restructures; Hana gets fast track; The best drug launches of all time; and much more...

> Bird flu has killed a woman on Indonesia's Bali island, making her the country's 84th fatality. Report

> Antigen Express, a subsidiary of Generex, and the University of Rochester will collaborate on a novel avian flu vaccine. Release

> Deltagen, which markets research tools to drug discoverers, has announced a restructuring that includes the termination of its VP of operations and a salary cut for company officers. Release

> Hana Biosciences' Marqibo has been fast tracked by the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second relapse or who have failed two lines of prior therapy. Release

> Nuvelo has enrolled the first patient in the SONOMA-3 trial evaluating its lead product candidate, alfimeprase. Release

> DNA2.0 and Operon Biotechnologies have formed a partnership. Release

> It turns out that just a teaspoon of waste water from a city's sewage treatment plant will give you a good snapshot of the drugs--both legal and illegal--used by the city's inhabitants. Report

> Investigators have determined that a common virus may play a key role in promoting obesity in some people. FierceBioResearcher

> Hostile takeovers are no fun to be part of but they're exciting to watch. Roche won the latest round in its bid for Ventana Medical Systems: An Arizona court granted an injunction against Ventana's use of anti-takeover statutes to block Roche's bid for the company. FiercePharma

> Novartis CEO Daniel Vasella says he's scrapping plans to invest millions in R&D in India. The reason? Intellectual property protections aren't adequate in India, according to Vasella. FiercePharma

And Finally… The best drug launches of all time. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.